Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    95
    ...
ATC Name B/G Ingredients Dosage Form Price
M01AB05 VOLDIC-K G Diclofenac potassium - 50mg 50mg Tablet 239,204 L.L
N01BB01 BUPIVACAINE AGUETTANT 5MG/ML G Bupivacaine HCl - 100mg/20ml 100mg/20ml Injectable solution 3,078,743 L.L
N03AX09 LAMOTRIGINE ARROW LAB G Lamotrigine - 50mg 50mg Tablet, dispersible/ chewable 1,052,229 L.L
N05BA12 ALPROX G Alprazolam - 0.5mg 0.5mg Tablet 383,955 L.L
P01BA02 CORVAQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, film coated 1,087,873 L.L
R05X COLDIN G Glyceryl guaiacolate - 15mg/5ml, Pseudoephedrine HCl - 15mg/5ml, Pyrilamine maleate - 6.25mg/5ml, Paracetamol - 120mg/5ml Syrup 386,515 L.L
V03AC03 ENFEROX G Deferasirox - 500mg 500mg Tablet, dispersible 37,720,158 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 895,895 L.L
B05CX01 SERUFLEX DEXTROSE 5% INJECTION USP G Glucose - 5% 5% Injectable solution 171,228 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C09CA04 ANDARAN G Irbesartan - 150mg 150mg Tablet, film coated 940,435 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 80mg 80mg Tablet, coated 564,414 L.L
D10AD01 KETREL G Tretinoin - 0.05% 0.05% Cream 397,777 L.L
G04BE08 TYRA G Tadalafil - 20mg 20mg Tablet, film coated 1,369,376 L.L
J01CR05 PIPERACILINA/TAZOBACTAM SALA G Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g Injectable powder for solution 913,813 L.L
J01MA02 ESTECINA 500MG G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 618,168 L.L
L01EB02 TARESSA 150 G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 98,617,813 L.L
L02BG04 FEMAPLEX G Letrozole - 2.5mg 2.5mg Tablet, film coated 1,583,046 L.L
M01AB15 KETOLAC G Ketorolac trometamine - 10mg 10mg Tablet 106,164 L.L
N01BB02 LIDOCAINE ARWAN G Lidocaine (HCl) - 0.5% 0.5% Injectable solution 1,995,158 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 50mg 50mg Tablet, dispersible 985,037 L.L
N05BA12 PAZOLAM G Alprazolam - 0.5mg 0.5mg Tablet 563,070 L.L
P01BA02 DOLQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, coated 1,191,988 L.L
R05X COLD-MED G Glyceryl guaiacolate - 15mg/5ml, Pseudoephedrine HCl - 15mg/5ml, Pyrilamine maleate - 6.25mg/5ml, Paracetamol - 120mg/5ml Syrup 386,515 L.L
V03AC03 DEFERASIROX ARROW G Deferasirox - 90mg 90mg Tablet, coated 8,846,092 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 5,916,747 L.L
B05CX01 SERUFLEX DEXTROSE 5% INJECTION USP G Glucose - 5% 5% Injectable solution 158,587 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 50mg 50mg Tablet, coated 1,849,127 L.L
C09CA04 CONVERIUM G Irbesartan - 150mg 150mg Tablet 585,915 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 80mg 80mg Tablet, coated 564,414 L.L
    ...
    95
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025